Business Context and Reporting Period
Company: Elicio Therapeutics, Inc. (ELTX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Elicio is a clinical-stage biotechnology company developing lymph node-targeted immunotherapies for cancer. Its proprietary Amphiphile (AMP) technology delivers payloads to lymph nodes to generate robust T-cell responses. The lead product candidate, ELI-002, is a cancer vaccine targeting mutant KRAS cancers currently in a Phase 2 trial (AMPLIFY-7P). The company also has preclinical candidates ELI-007 (mutant BRAF) and ELI-008 (mutant TP53).
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(51,898) | $(35,195) |
| Research & Development Expenses | $33,656 | $23,849 |
| General & Administrative Expenses | $11,330 | $11,896 |
| Cash and Cash Equivalents (Year End) | $17,618 | $12,894 |
| Accumulated Deficit | $(194,101) | $(142,203) |
| Net Cash Used in Operating Activities | $(37,068) | $(32,694) |
| Net Cash Provided by Financing Activities | $42,321 | $38,613 |
Debt: As of December 31, 2024, the company held a $20.0 million Senior Secured Convertible Note (related party). Note: Subsequent to year-end, on March 5, 2025, this note was fully converted into common stock.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by 47.5% to $51.9 million in 2024 from $35.2 million in 2023. This was driven primarily by a $9.8 million increase in R&D expenses and a $7.5 million swing in "Other (expense) income" from a net gain in 2023 to a net loss in 2024.
- R&D Expenses: Increased 41.1% year-over-year due to higher external costs associated with ELI-002 manufacturing and clinical trials.
- Other Income/Expense: The shift from income to expense was primarily due to changes in the fair value of warrant liabilities and losses on the issuance of pre-funded and common warrants.
- Financing Activity: The company raised significant capital in 2024, including $19.7 million from a convertible note and proceeds from public offerings and warrant issuances, resulting in a net cash increase of $5.2 million for the year.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Uncertainty
The company has identified conditions that raise substantial doubt about its ability to continue as a going concern. Management believes current cash resources will fund operations into the fourth quarter of 2025. The independent auditor has included an explanatory paragraph regarding this uncertainty in their report.
Clinical Outlook
- ELI-002 (KRAS): Enrollment in the randomized Phase 2 AMPLIFY-7P trial was completed in December 2024. An interim analysis based on disease-free survival events is expected in Q3 2025.
- Pipeline: Preclinical programs ELI-007 and ELI-008 are advancing, with the company seeking collaborations to move them into Phase 1 trials.
Material Weaknesses in Internal Controls
The company identified material weaknesses in internal control over financial reporting related to the control environment, specifically regarding the review of complex transactions and period-end accruals. While remediation efforts (hiring staff, engaging consultants) have begun, these weaknesses were not fully remediated as of December 31, 2024.
Unusual Items
- Warrant Liability Volatility: Significant non-cash losses were recorded due to the re-measurement of warrant liabilities (pre-funded and common warrants) issued in 2024.
- Related Party Transactions: A significant portion of recent financing (March 2024 private placement and August 2024 convertible note) involved GKCC, LLC, an entity controlled by a board member.
Key Facts for Investor Verification
- Cash Runway: Verify the company's ability to raise additional capital before Q4 2025 to avoid operational delays or liquidation.
- Phase 2 Trial Data: Monitor the timing and results of the AMPLIFY-7P interim analysis expected in Q3 2025, which is critical for future valuation and funding.
- Internal Controls: Track the progress of remediation efforts for the identified material weaknesses in financial reporting controls.
- Debt Conversion: Confirm the impact of the March 2025 conversion of the $20 million convertible note into equity on share count and dilution.
- Grant Funding: Review the status of GI Research Foundation grants, which offset a portion of R&D expenses but are subject to specific performance milestones.